Close this search box.

We are creating some awesome events for you. Kindly bear with us.

AI-Powered Engine Delivers Preclinical Candidate for Kidney Fibrosis

A global company specialising in the applications of the next-generation machine learning technologies for drug discovery and development announced that its AI-powered drug discovery platform has delivered the preclinical candidate (PCC) for kidney fibrosis.

The preclinical candidate has the desirable pharmacological properties, pharmacokinetic profile, and demonstrated highly promising results in in vitro and in vivo preclinical studies. Work is being done to advance this program to clinical trials.

The company’s Founder and CEO stated that chronic kidney disease affects 10% of the world’s population, and, unfortunately, it has no cure or efficacious drugs on the market. Kidney fibrosis is the common pathogenesis in the progression of chronic kidney disease (CKD) and is a major unmet medical need.

The AI-powered drug discovery engine has uncovered novel targets and novel molecules that have demonstrated preclinical efficacy in kidney fibrosis. Moreover, the company’s used its InClinico engine to produce the actuarial models for multiple diseases driven by kidney fibrosis and are very excited about the clinical prospects of this program.

The Head of BioMedical Technology Cluster of HKSTP stated that biomedical technology is a strategic focus for both HKSTP and Hong Kong’s position as an innovation and technology hub. The Park is excited to witness a partner company achieve yet another milestone, which has been relentlessly striving to transform the future of drug discovery and development through AI. The discovery of the preclinical candidate further enhances HKSTP’s thriving biomedical technology ecosystem and strengthens Hong Kong’s broader position as a world-class hub in this space.

A significant breakthrough was made in February 2021 when the company announced that its AI system identified a novel drug target and novel compound to treat idiopathic pulmonary fibrosis (IPF), which is another fibrotic disease affecting patients worldwide with high unmet medical needs. What also made the discovery noteworthy was that this was achieved within 18 months and a $2.6 million budget.

Repeating that success, the firm’s PandaOmics developed the target hypothesis for kidney fibrosis and used Chemistry42 to generate compounds with drug-like properties. The compound that markedly inhibited the development of fibrosis and significantly improved myofibroblast activation is critical for tissue repair and wound healing. The IND-enabling studies for this program are expected to be completed in 2022.

Global biomedical ICT market expected to grow

According to recent research, the biomedical ICT market is expected to reach US$57 billion by 2025. The field of biomedicine is concerned with the application of various natural science disciplines for the development of knowledge, interventions, and/or technologies for use in healthcare.

The Information and Communications Technology sector focuses on telecommunications, computing, and the integration of both. Related to ICT is the term TMT, which more broadly refers to Technology, Media, and Telecom. Both are related to the use of various digital technologies for communications, applications, commerce, and content. The convergence of biomedical and ICT represents a high opportunity area for both healthcare and ICT industries.

In addition to seeking cures to disease and ailment prevention, the convergence of biomedical and ICT technologies and solutions will lead to improved treatment efficacy as well as overall improvements in healthcare service delivery efficiency and effectiveness.

Various ICT tools may be employed such as IoT enabled monitoring to determine the effectiveness of medical procedures, which can be especially important when administering new and unproven healthcare modalities.

One specific example is the administration of vaccines, which is believed to potentially cause harm to a subset of the population based on epigenetics, which is the study of changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself. This is believed to be an area in which a healthcare modality is designed with one intent (to inoculate one to prevent the onset of disease), but may actually trigger unintended consequences such as causing harm based on an individual’s unique gene expression.

With healthcare costs growing much faster than the general inflation rate, it is of the utmost importance to simultaneously seek improved treatment while continuously driving down business costs. These costs include ongoing operational expenditures as well as expensive R&D such as drug discovery and other pharmaceutical-related areas such as vaccine development that takes into account precision medicine practices.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.